The utility of mass spectrometry-based proteomic data for validation of novel alternative splice forms reconstructed from RNA-Seq data: a preliminary assessment
2010

Using Mass Spectrometry to Validate New Protein Variants from RNA-Seq Data

publication Evidence: low

Author Information

Author(s): Ning Kang, Alexey I. Nesvizhskii

Primary Institution: University of Michigan

Hypothesis

Can mass spectrometry-based proteomics validate novel alternative splice forms identified from RNA-Seq data?

Conclusion

The study found that the ability to confirm novel alternative splice forms from mass spectrometry data was quite limited due to low abundance of many novel transcripts.

Supporting Evidence

  • A significant correlation was observed between the likelihood of identifying a peptide from MS data and the number of reads in RNA-Seq data for the same gene.
  • Only a fraction of novel alternative splice forms identified from RNA-Seq had corresponding junction peptides compatible with MS sequencing.
  • The number of novel peptides identified from MS spectra was substantially lower than expected based on in silico analysis.

Takeaway

The researchers tried to see if they could find new proteins from RNA data using mass spectrometry, but they found it was really hard to do.

Methodology

The study used publicly available mouse tissue proteomic and RNA-Seq datasets to examine the feasibility of identifying novel alternative splice forms.

Limitations

The identification of novel peptides was lower than expected, and many novel transcripts were below the detection limit of mass spectrometry.

Digital Object Identifier (DOI)

10.1186/1471-2105-11-S11-S14

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication